. 2018 May 15;9(37):24707–24717. doi: 10.18632/oncotarget.25185

Table 1. Characteristics of the ovarian tumors from which EOC-xenografts derived.

	Patient’s original diagnosis				EOC-PDXs			Patient’s original diagnosis				EOC-PDXs
Xenograft ID	Histotype	Grade	Stage	Source	TP53	DDP response	Xenograft ID	Histotype	Grade	Stage	Source	TP53	DDP response
MNHOC239	serous	G2	IV	R	mut		MNHOC506	serous	G3	IIIC	n/a^*	mut
MNHOC241	serous	G2	IC	P	wt	n/a	MNHOC508	serous	G3	IIIC	P	mut
MNHOC244	serous	G2	IV	P	mut	n/a	MNHOC124	serous/endometrioid	G2	IIIC	P	mut
MNHOC250	serous	G3	IIIC	P	mut	n/a	MNHOC212	serous/endometrioid	G2	IIIC	P	mut
MNHOC258	serous	G3	IIIC	P	mut		MNHOC154	endometrioid	G2	IIC	R	mut
MNHOC266	serous	G2	n/a	n/a^*	mut		MNHOC218	endometrioid	G3	IIIC	P	mut
MNHOC76	serous	G3	IIIC	R^*	mut		MNHOC230	endometrioid	G3	IIB	R	mut
MNHOC18	serous	G3	IV	P	mut		MNHOC261	endometrioid	G2	IIIC	P	mut
MNHOC8	serous	G3	IV	P^*	mut		MNHOC78	endometrioid	G2	IIIC	R	mut
MNHOC107	serous	G3	IIIC	R	mut		MNHOC109	endometrioid	G2	IC	R	wt
MNHOC111/2	serous	G3	IIIC	R^*	mut		MNHOC503	endometrioid	G3	IIIA	P	wt
MNHOC22	serous	G3	III	R^*	mut		MNHOC145	endometrioid	G1	IC	P	n.a	n.a
MNHOC10	serous	G3	IIIC	P^*	mut		MNHOC79	endometrioid/clear cell	G3	IIIC	R^*	mut
MNHOC8Y	serous	G3	IV	R^*	mut		MNHOC164	mucinous	G2	IV	P	wt
MNHOC84	serous	G3	IIIC	R	mut		MNHOC182	mucinous	G1	IC	P	wt
MNHOC106C	serous	G3	IIIC	R	mut		MNHOC119	clear cell	G3	IC	P	wt
MNHOC94/2C	serous	G2	IA	R	wt		MNHOC142	clear cell	G3	IIIC	P^*	mut
MNHOC125	serous	G3	IV	P	mut		MNHOC135	mixed mullerian	G3	IIIB	P	mut
MNHOC143	serous	G3	IIIC	P	mut		MNHOC151	carcinosarcoma	G3	IIB	P	n.a	n.a
MNHOC149	serous	G3	IIIC	P	mut	n.a	MNHOC9	not classified	na	IIIC	P	mut
MNHOC500	serous	G3	IIIC	P	mut		MNHOC88	undifferentiated	G3	IIIC	R	mut

Abbreviations: EOC: epithelial ovarian carcinoma; PDXs: patient derived xenografts; P: primary tumor; R: relapse; mut: mutated; wt: wild type; n.a: not available. ^*Tumor cell suspension transplanted intraperitoneal (ip).

^*DDP response: in vivo activity of DDP as described in Material and Methods. Drug activity was defined as follows: subcutaneous tumors were considered resistant with T/C ≥ 50% (black), responsive with 10 to 50% T/C (dark grey) and very responsive with T/C ≤ 10% (light grey); intraperitoneal tumors were considered resistant with Increase in Life Span (ILS) ≤ 40%, responsive with 40 to 100% ILS, and very responsive with ILS ≥ 100%, according to published criteria.